Drug Device Combination Products Market Report 2025 (Global Edition)

Global Drug Device Combination Products Market Report 2025 Market Size Split by Type (Drug Eluting Stents, Transdermal Patches, Infusion Pumps, Drug Eluting Balloon, Inhalers, Other Products), by Appl...

Drug Device Combination Products Market Report Description

We have various report editions of Drug Device Combination Products Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape: Drug-Device Combination Products market

This market is estimated to offer tremendous growth opportunities to the vendors during the forecast period. Vendors that can efficiently manufacture and offer a wide variety of drug-device combination products, such as infusion pumps, insulin injections, and drug-eluting stents, are expected to gain a competitive edge over their rivals.

The key players in the drug-device combination products market are actively engaged in strategic initiatives to maintain their competitive edge and drive market growth. These initiatives include extensive research and development (R&D) efforts aimed at introducing novel combination therapies that offer improved therapeutic outcomes and patient convenience. Additionally, companies are focusing on expanding their product portfolios through acquisitions, partnerships, and collaborations with other industry stakeholders. These strategic alliances enable companies to leverage complementary expertise, technologies, and resources to accelerate product development and market penetration. 

Moreover, key players are investing in marketing and promotional activities to raise awareness about their products and enhance their market presence. Furthermore, efforts are being made to strengthen regulatory compliance and quality assurance processes to ensure product safety and efficacy. Additionally, companies are exploring opportunities in emerging markets by establishing local manufacturing facilities and distribution networks to cater to the growing demand for combination products in these regions.

Some of the major market players in the drug device combination products industry include Abbott Laboratories, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Boston Scientific Corporation, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Novartis AG, Smith & Nephew plc, Stryker Corporation, Terumo Corporation, etc.

Recent Market Developments:

• September 2022- The SENTINELTM Cerebral Protection System, which is intended to capture and remove embolic debris from the transcatheter aortic valve replacement (TAVR) before it can reach the brain and potentially cause a stroke, was evaluated in the PROTECTED TAVR clinical trial, according to results released by Boston Scientific Corporation. The 34th Transcatheter Cardiovascular Therapeutics, the annual scientific conference of the Cardiovascular Research Foundation, was held in Boston. Results were presented during the late-breaking clinical science session and will be published in the New England Journal of Medicine. 

(Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2204961)

• June 2020: Abbott announced the launch of its new drug device combination product, the FreeStyle Libre 2 system, in the United States. This system integrates Abbott's continuous glucose monitoring (CGM) technology with a wearable sensor and a mobile app, allowing individuals with diabetes to monitor their glucose levels continuously without the need for fingerstick tests. The FreeStyle Libre 2 system offers improved accuracy and reliability compared to previous models, providing patients with real-time insights into their glucose levels and helping them make more informed decisions about their diabetes management. 

(Source; https://abbott.mediaroom.com/2020-06-15-Abbotts-FreeStyle-R-Libre-2-iCGM-Cleared-in-U-S-for-Adults-and-Children-with-Diabetes-Achieving-Highest-Level-of-Accuracy-and-Performance-Standards)

Top Companies Market Share in Drug Device Combination Products Industry: (In no particular order of Rank)

• Abbott Laboratories
• Medtronic Plc
• Stryker Corporation
• Smith Nephew Plc
• Ethicon Inc.
• C.R. Bard Inc
• Boston Scientific Corporation
• Cook Medical
• St. Jude Medical Inc.
• Zimmer Holdings Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which Region will dominate the Market in 2024, and Which Region is Expanding at the Fastest CAGR?

The North American region has dominated the Drug Device Combination Products Market. North America is the most significant shareholder in the global drug-device combination products market and is anticipated to grow at a CAGR of XX% over the forecast period. The market for medication device combination products is expected to be dominated by the United States over the forecast period due to the rising prevalence of chronic diseases and the growing elderly population. In 2020, there were anticipated to be 612,390 cancer-related fatalities in the United States and 2,281,658 newly diagnosed cases of the disease. Breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, and skin cancer are the most prevalent malignancies in the US. The prevalence of other chronic diseases is also rising in the US and leading to heart disease, which places a heavy burden on individuals, communities, healthcare providers, and systems.

The European Drug Device Combination Products Market is anticipated to grow at the fastest CAGR from 2023 to 2032. Europe is expected to grow at a CAGR of XX%, generating USD XX billion during the forecast period. The nation also boasts a sizable number of businesses engaged in the healthcare industry. The number of TIA and stroke cases treated in German hospitals increased between 2011 and 2017, according to a 2019 study titled "Inpatient transient ischemic attack (TIA) and stroke care in adult patients in Germany -a retrospective analysis of countrywide administrative data sets of 2011 to 2017." It is anticipated that the extremely high rate of cancer-related deaths will increase demand for innovative drug and device combination products over the forecast period.

The current report Scope analyzes Drug Device Combination Products Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Drug Device Combination Products Market Analysis

How is the Product Types Segment Performing in the Drug Device Combination Products Market?

Based on Product Type, the Inhalers segment dominates the global Drug Device Combination Products market in the year 2023. Based on this product type, the market is divided into drug-eluting stents, infusion pumps, inhalers, and others.

The inhalers segment is the highest contributor to the market and is expected to grow at a CAGR of XX% during the forecast period. In this inhaler drug delivery system, the patient inhales a mist or spray formulation of the medication. Inhalers are a convenient and accurate method for administering medication directly to the lungs. The two types are metered dose inhalers, commonly referred to as puffers, and dry powder inhalers. The prevalence of chronic respiratory disorders, including COPD and asthma, among others, is one of the main contributors to the growth of the inhaler market. Additionally, market participants are focused on introducing cutting-edge items into the market while implementing various growth tactics. A high-tech add-on is a pMDI inhaler that can be attached to asthma and COPD rescue medications. It records information about each drug use and the conditions surrounding it.

Drug-eluting stents (DES) have emerged as the dominant segment in the global drug-device combination product market, primarily due to their superior outcomes, technological advancements, and robust clinical evidence. DES is the preferred choice for treating cardiovascular diseases, supported by high demand, continuous innovations, and regulatory acceptance. These factors have solidified the position of DES as the leading product type in the market.

For instance, on May 13, 2022, Medtronic plc, announced U.S. FDA approval for the Onyx Frontier drug-eluting stent. This latest advancement in stent technology enhances deliverability and acute performance in treating coronary artery disease (CAD), showcasing Medtronic's commitment to innovative solutions in interventional cardiology.

• Drug Eluting Stents
• Transdermal Patches
• Infusion Pumps
• Drug Eluting Balloon
• Inhalers
• Other Products

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Drug Device Combination Products Industry. Request a Free Sample PDF!

Which application segment holds the largest revenue share of the Drug-Device Combination Products Market?

Based on Application, the respiratory diseases segment dominated the global Drug Device Combination Products market. Based on Application, the global Drug Device Combination Products market is segmented into Cardiovascular, Diabetes, Cancer Treatment, Respiratory Diseases, and Other Applications.

The respiratory diseases segment owns the highest market share and is expected to grow at a CAGR of XX% during the forecast period. According to the National Center for Health Statistics, 2020, in the United States, physician ambulatory-care visits for respiratory disorders were highest in people over 85. It was 57% lower in people between the ages of 75 and 84 and 85% lower in those between the ages of 65 and 74. This market is anticipated to expand considerably more throughout the projection periods as a result of the introduction of the novel coronavirus and the rapid spread of the disease. For instance, Purchase, a new portable and ready-to-use delivery solution created for upper respiratory care in 2018 was introduced by Aptar Pharma in the United States. It is used in conjunction with saline or other natural ingredient formulations to help relieve the symptoms of upper respiratory system conditions.

The most common type of disease proven to exist worldwide is cardiovascular disease, which is also one of the leading causes of death. In India, drug-eluting stents are used in roughly 95% of percutaneous coronary intervention (PCI) cases, according to Diagnostic and Interventional Cardiology, 2020. The demand for these stents increased in 2018 after the Indian National Pharmaceutical Pricing Authority (NPPA) lowered the cost of drug-eluting stents by roughly USD 33. The number of new products being released in the field is anticipated to increase along with the disease's increasing incidence on a global scale.

• Cardiovascular
• Diabetes
• Cancer Treatment
• Respiratory Diseases
• Other Applications

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Drug Device Combination Products End Users Segment Analysis

Based on end users,  the Hospitals segment dominated the global Drug Device Combination Products market. Based on end-users, the global Drug Device Combination Products market is segmented into hospitals, ambulatory surgical centers, and others.

The hospital segment is the highest contributor to the market and is expected to grow at a CAGR of XX% during the forecast period. Modern technical equipment is well-equipped in hospitals to provide better treatments. Due to the rising number of patients with chronic conditions, the hospital category is expanding quickly. Combination therapy, also known as medication device combination, is used in most medical fields where treatment is complex, such as chemotherapy, because of its benefits, low costs, and straightforward formats. Growing healthcare infrastructure in emerging economies and assistance from government agencies are also assisting in developing drug-device combination products market sector.

ASCs, or ambulatory surgery centers, are cutting-edge medical establishments that provide same-day surgical care, including diagnostic and preventive procedures. The Healthcare Advisory Board estimates that the volume of ASC procedures will likely increase by 27.6% by 2027. Predictions indicate that by the middle of the 2020s, almost 50% of all cardiovascular systems will be conducted in an ASC. Compared to hospital stays, ASC operations often have lower co-pays. In addition to making scheduling and facility access easier, ASC reduces patient wait times. A more reasonable price and a caring clinical staff combine to create an excellent patient-centric experience. Together with the rising use of combination therapies in ambulatory surgery centers, these elements accelerate the segment's rise.

• Hospitals
• Ambulatory Surgical Centers
• Other End-Users

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion